Literature DB >> 20395518

A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma.

Stephanie D Schniederjan1, Shiyong Li, Debra F Saxe, Mary J Lechowicz, Kathryn L Lee, Paul D Terry, Karen P Mann.   

Abstract

Rapid and accurate differential diagnosis between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL) is imperative because their treatment differs. Recent studies have characterized several antigens differentially expressed in these 2 types of lymphoma. Our goal was to determine whether use of these markers would aid in the differential diagnosis of BL vs CD10+ DLBCL by flow cytometric immunophenotyping (FCI). Twenty-three cases of CD10+ B-cell lymphomas with available cryopreserved samples were identified (13 BL and 10 CD10+ DLBCL). Multiparameter FCI was performed using the following antibodies: CD18, CD20, CD43, CD44, and CD54 and isotype controls. Expression of CD44 and CD54 was detected at a significantly lower level in BL compared with CD10+ DLBCL (P = .001 and P = .01, respectively). There was not a significant difference in expression of CD18 and CD43. Our data show that expression of CD44 and CD54 differs significantly between BL and CD10+ DLBCL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20395518     DOI: 10.1309/AJCP0XQDGKFR0HTW

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

1.  Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system.

Authors:  Paul McGowan; Nicole Nelles; Jana Wimmer; Dawn Williams; Jianguo Wen; Marilyn Li; April Ewton; Choladda Curry; Youli Zu; Andrea Sheehan; Chung-Che Jeff Chang
Journal:  Am J Clin Pathol       Date:  2012-04       Impact factor: 2.493

2.  CD44 expression in intraoral salivary ductal papillomas and oral papillary squamous cell carcinoma.

Authors:  Sarah G Fitzpatrick; Lindsay J Montague; Donald M Cohen; Indraneel Bhattacharyya
Journal:  Head Neck Pathol       Date:  2012-11-13

3.  Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls.

Authors:  Iole Cordone; Serena Masi; Mariantonia Carosi; Antonello Vidiri; Francesco Marchesi; Mirella Marino; Stefano Telera; Alessia Pasquale; Andrea Mengarelli; Laura Conti; Edoardo Pescarmona; Andrea Pace; Carmine M Carapella
Journal:  J Exp Clin Cancer Res       Date:  2016-08-27

4.  Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms.

Authors:  Elissandra Machado Arlindo; Natália Aydos Marcondes; Flavo Beno Fernandes; Gustavo Adolpho Moreira Faulhaber
Journal:  Rev Bras Hematol Hemoter       Date:  2017-05-29

5.  Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.

Authors:  Heyjin Kim; Hee-Jin Kim; Sun-Hee Kim
Journal:  Ann Lab Med       Date:  2020-09       Impact factor: 3.464

6.  Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis.

Authors:  Kamila Duś-Szachniewicz; Grzegorz Rymkiewicz; Anil Kumar Agrawal; Paweł Kołodziej; Jacek R Wiśniewski
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

7.  Non-invasive bioluminescence imaging to monitor the immunological control of a plasmablastic lymphoma-like B cell neoplasia after hematopoietic cell transplantation.

Authors:  Martin Chopra; Sabrina Kraus; Stefanie Schwinn; Miriam Ritz; Katharina Mattenheimer; Anja Mottok; Andreas Rosenwald; Hermann Einsele; Andreas Beilhack
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

8.  Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens.

Authors:  Wei Wang; Yan Li; Haval Ali; Linjun Zhao; Di Mei; Wenqing Hu; Bin Jiang
Journal:  BMC Cancer       Date:  2021-12-08       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.